Crispr Therapeutics Viking Therapeutics: 2026 Stock Showdown
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Discover which cards have the best benefits to maximize your rewards. Make informed choices for better financial outcomes.
26,924 articlesAs biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
AppLovin rode a massive multi-year rally, but a pivot to pure-play ad tech and a softening macro beat have investors ...
Roku stock has slipped about 17% year-to-date, even as the company shows improving profitability and optimism for gro...
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
MercadoLibre's fourth-quarter results showed strong revenue growth, but a notable drop in profitability. This article...
Nvidia has dazzled investors with AI-driven growth, but a hidden threat could derail the rally. This article identifi...
A bold contrarian wager on semiconductors has underperformed as AI demand sustains a rally. Leveraged, daily-reset fu...
Navitas NVTS and ON Semiconductor are capturing attention as AI data-center demand climbs. Analysts see a potential r...
Mortgage lenders enter 2026 with a mandate to slash inefficiencies while preserving compliance. This snapshot capture...
A high-profile clash between the Pentagon and a leading AI firm hits markets and wallets. Regulators, investors, and ...
A tiny stock in the nuclear space could offer outsized gains if key milestones hit. Learn how to evaluate the opportu...
Peter Thiel's AI warning collides with rising demand for storytellers, prompting a reassessment of career paths and p...